Phase III clinical evaluation of ribociclib + endocrine therapy (fulvestrant/letrozole) in HR+/HER2- ABC patients; tumor response assessed by CT, mammogram, ultrasound, and bone scan per RECIST v1.1; safety monitored via CTCAE v4.0; histopathological assessment post-therapy; patient-reported outcomes and QoL evaluations included. This evidence concerns the gene ERBB2 and neoplasm.